


# Developing Reference Measurement Procedures in Compliance with ISO 15193

Dr. Anja Kessler
Reference Institute for Bioanalytics
Bonn, Germany

## Differences between Routine Analysis and RMP



## **Definition of RMP**



#### Reference Measurement Procedure


Measurement procedure accepted as providing measurement results fit for their use in assessing measurement trueness of measured quantity values obtained from other measurement procedures for quantities of the same kind, in calibration, or in characterizing reference materials.

(ISO/IEC Guide 99:2007, 2.7)

- The RMP has to be validated for the quantity which is intended to be measured.
- RMP can be part of a reference measurement system to assess measurement trueness of other measurement procedures within a calibration hierarchy.

## Role of RMP





RMPs that comprise elements of a calibration hierarchy and that meet the requirements of ISO 15193 has to be considered as MPs of higher metrological order.

## **ISO 15193**



In vitro diagnostic medical devices –

Measurement of quantities in samples of biological origin –

Requirements for content and presentation of reference

measurement procedures (ISO 15193:2009)

# Mandatory Elements of RMP according to ISO 15193



Title page

Warning and safety precautions

Title of RMP

Scope

Measurement principle and method

Reagents

**Apparatus** 

Sampling and sample

Preparation of measuring system and analytical portion

Operation of measuring system

Data processing

Analytical reliability

Validation by inter-laboratory comparisons

Reporting

Quality assurance

Date of authorization and revision

# Mandatory Elements of RMP according to ISO 15193



Title page

Warning and safety precautions

Title of RMP

Scope

Measurement principle and method

Reagents

**Apparatus** 

Sampling and sample

Preparation of measuring system and analytical portion

Operation of measuring system

Data processing

Analytical reliability

Validation by inter-laboratory comparisons


Reporting

Quality assurance

Date of authorization and revision

## Measurement principle and method





Measurement principle e.g.IDMS

Method description comprises
all steps like addition of internal
standard, preparation of samples
and calibrators, quantitative
determination, and calculation.

# Preparation of measuring system and analytical portion



### Calibration

The principle, materials and steps have to be described in detail:

- choice of calibration procedure (number of calibration points, equation, bracketing, ...)
- suitable calibrators (check for metrological traceability, ...)
- calibrator preparation (e.g. gravimetric/volumetric preparation, standard addition technique, ...)
- measurement of calibrators
- method of computing a monotonic calibration function and the measurement uncertainties of its parameters
- acceptance of calibration function
- time interval of recalibration within and/or between series



## **Data Processing**




### Calculation of measurement results

The procedure for calculation has to include:

- processing of validated initial data (including blank correction, repeated values)
- construction of measuring function
- the quantity and its measurement unit
- the model for statistical treatment
- the complete equation for calculation
- the description of any algorithm used
- the minimum number of points
- the number of replicate measured values
- calculation of measurement uncertainty

## **Measurement Uncertainty**





Each values has its measurement uncertainty.

It should be an objective in developing a RMP to eliminate all known causes of effects as far as possible.

But note:

It's not getting less, if you don't look at.

## **Analytical reliability**



## Measurement uncertainty (MU)

MU comprises many components. The MU of random effects should be evaluated from statistical distribution of values from series of measurements.

MUs caused by systematic effects have to be add to the uncertainty budget, e.g. impurity of RM, calibrated volumetric equipment, or balances









## Validation of a RMP



A RMP should be validated to show that it is fit for its intended use.

The validation has to be as extensive as necessary and includes:

- comparison of results achieved with other procedures
- interlaboratory comparisons
- performance validation using reference materials (matrix-based CRM)
- assessment of the measurement uncertainty based on scientific understanding and practical experience.

## Interlaboratory comparisons





#### **RELA - Homepage**

External quality control for Reference Laboratories



Home

#### Welcome

login

Registration/ Accou

### **RELA - IFCC External Quality assessment scheme for Reference Laboratories in Laboratory Medicine**

This site gives you all the information you will need for participating in the RELA scheme.

Time schedule for the annual surveys (may vary slightly)

#### **RELA in progress**

order RELA 2018

enter RELA 2018 results

#### **Announcement: September 1**

Deadline for ordering: September 30 **Shipment of samples: October 15** 

Deadline for transmission of results: April 15 (following year)

Reporting results to participants: May 15 **Publishing results on this website: June 15** 

#### Please refer to the navigation area on the left to (for instructions see our new RELA web manual)

- register or log in
- order the survey
- entering your results
- get the evaluation of past surveys

The whole RELA process is described in detail in the IFCC-RELA-EQAS procedure manual.

#### former RELA results

Choose year...

#### Offered measurands:

Metabolites and substrates (META): total cholesterol, total glycerol, creatinine, uric acid, urea, glucose, total bilirubine

Electrolytes (ELEC): sodium, potassium, chloride, calcium, lithium, magnesium

Enzymes (ENZY): ALT, AP, AST, CK, LDH, GGT, amylase

Glycated hemoglobins (GLYC): HbA1c

**Proteins (PROT):** total protein

Hormones (HORM): aldosterone, cortisol, progesterone, testosterone, estradiol-17ß, estriol, 17-OH-progesterone

Thyroid hormones (THYR): total thyroxine (TT4), total tri-iodthyronine (TT3),


Therapeutic drugs (THER): digoxin, digitoxin, theophylline

Vitamins (VITA): 25-OH-vitamin D3

# **Interlaboratory comparisons**

### **Example: Estriol, unconjugated**





show result plot

with limits of equivalence

For highlighting a specific result please click on the

corresponding result line.

Result lines printed in bold indicate JCTLM listed services.

Labcode	A	e.u.	В	e.u. B	Method
1	3.349	0.033	9.81	0.13	ID/GC/MS
51	3.32	0.07	9.74	0.16	ID/LC/MS/MS
54	3.54	0.21	9.46	0.19	ID/LC/MS/MS
65	3.64	0.15	9.91	0.34	ID/LC/MS/MS
87	3.35	0.2	9.85	0.42	ID/LC/MS/MS
134	3.385	0.137	9.619	0.206	ID/LC/MS/MS

Different RMP

2 labs listed JCTLM

Comparison of MU

A Min 1.0 % Max 5.9 %

B Min 1.3 % Max 4.3 %

MUs do not have to be the same. Comparison of MUs can give hints of underestimation \ \bar{\cut} \ or errors in processing RMP \ \bar{\cut} \.

Results of candidate RMP can be compare to established (and JCTLM listed) RMP, too.

e.u. - expanded uncertainty

## **JCTLM** and its database





Database of higher-order reference materials, measurement methods/procedures and services



JCTLM WG reviews nominations of RMP based on ISO Guide 15193 and their individual expertise.

Currently 194 RMP for 81 unique measurands are listed in the JCTLM database; 23 RMP for 20 different peptides.

https://www.bipm.org/en/committees/jc/jctlm/jctlm-nominations-and-review.html

# **RMP – JCTLM Database Entry**



Isotope dilution mass spectrometry methods for amyloid beta 1-42 in other				
▶ 2D-UPLC-tandem mass spectrometric method for analysis of amyloid beta 1-42 in human CSF				
Applicable matrice(s)	frozen human cerebrospinal fluid (CSF)			
Full description of technique(s)	Liquid chromatography tandem mass spectrometry, solid phase extraction			
Quantity	Mass concentration			
Applicable range	100 pg/mL to 3000 pg/mL			
Expected uncertainty (level of confidence 95%)	14.3 pg/mL to 355.2 pg/mL			
Reference(s)	Qualification of a surrogate matrix-based absolute quantification method for Amyloid β <sub>42</sub> in human cerebrospinal fluid using 2D UPLC-Tandem Mass Spectrometry, Korecka M et al., Journal of Alzheimer's Disease (JAD), 2014, <b>41</b> (2), 441-451			
Comparability assessment study(ies)	Clinical comparison with immunoassay as cited in: Korecka M et al., $JAD$ , 2014, <b>41</b> (2), 441-451 Round robin test on quantification of amyloid- $\beta$ -1-42 in cerebrospinal fluid by mass spectrometry, Pannee J et al., Alzheimer's and Dementia, 2016, <b>12</b> (1), 55-59			
Comment(s)	The reference measurement method, C12RMP1, for quantification of $A\beta42$ in cerebrospinal fluid was developed and validated by the Biomarker Research Laboratory of Perelman School of Medicine, University of Pennsylvania			
JCTLM DB identification number	C12RMP1			

## Use of RMP



#### RMP can be used

- to assess performance properties of routine procedures,
- to demonstrate if there is a functional interchangeability of different routine procedures,
- to assign values to reference materials used for calibration or trueness control (e.g. EQA schemes),
- to detect analytical influence quantities in patient samples.

## **Conclusions**



Developing a RMP comprises many different elements: from the detailed description of the measurement principle and all analytical steps to the estimation of measurement uncertainty, extensive analytical reliability and an unprejudiced validation.

The international standard ISO 15193 gives guidance through this process.

If an experienced laboratory worker applies your written RMP and produces measurement results with the same measurement uncertainty as you did, than the intention of the standard is met.